Krystal Biotech (NASDAQ:KRYS) Given New $220.00 Price Target at Chardan Capital

Krystal Biotech (NASDAQ:KRYS) had its target price raised by research analysts at Chardan Capital from $216.00 to $220.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price target indicates a potential upside of 11.20% from the stock’s current price.

KRYS has been the topic of several other reports. Citigroup reissued a “neutral” rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Bank of America raised their target price on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. HC Wainwright reissued a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Monday, September 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. Finally, Guggenheim set a $224.00 target price on Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $223.57.

Krystal Biotech Trading Up 0.2%

Shares of NASDAQ:KRYS opened at $197.85 on Tuesday. The stock’s 50-day moving average price is $170.39 and its 200-day moving average price is $152.92. Krystal Biotech has a 12-month low of $122.80 and a 12-month high of $207.84. The stock has a market capitalization of $5.73 billion, a P/E ratio of 40.21 and a beta of 0.65.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $97.80 million for the quarter, compared to analysts’ expectations of $93.72 million. As a group, research analysts predict that Krystal Biotech will post 6.14 EPS for the current year.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently made changes to their positions in KRYS. Soleus Capital Management L.P. increased its position in shares of Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after acquiring an additional 481,200 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after acquiring an additional 365,304 shares in the last quarter. Braidwell LP increased its position in shares of Krystal Biotech by 81.6% during the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after acquiring an additional 327,067 shares in the last quarter. Norges Bank bought a new stake in shares of Krystal Biotech during the second quarter valued at approximately $38,861,000. Finally, Nuveen LLC bought a new stake in shares of Krystal Biotech during the first quarter valued at approximately $42,223,000. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).